Literature DB >> 23220002

Neuropathy target esterase (NTE): overview and future.

Rudy J Richardson1, Nichole D Hein, Sanjeeva J Wijeyesakere, John K Fink, Galina F Makhaeva.   

Abstract

Neuropathy target esterase (NTE) was discovered by M.K. Johnson in his quest for the entity responsible for the striking and mysterious paralysis brought about by certain organophosphorus (OP) esters. His pioneering work on OP neuropathy led to the view that the biochemical lesion consisted of NTE that had undergone OP inhibition and aging. Indeed, nonaging NTE inhibitors failed to produce disease but protected against neuropathy from subsequently administered aging inhibitors. Thus, inhibition of NTE activity was not the culprit; rather, formation of an abnormal protein was the agent of the disorder. More recently, however, Paul Glynn and colleagues showed that whereas conventional knockout of the NTE gene was embryonic lethal, conditional knockout of central nervous system NTE produced neurodegeneration, suggesting to these authors that the absence of NTE rather than its presence in some altered form caused disease. We now know that NTE is the 6th member of a 9-protein family called patatin-like phospholipase domain-containing proteins, PNPLA1-9. Mutations in the catalytic domain of NTE (PNPLA6) are associated with a slowly developing disease akin to OP neuropathy and hereditary spastic paraplegia called NTE-related motor neuron disorder (NTE-MND). Furthermore, the NTE protein from affected individuals has altered enzymological characteristics. Moreover, closely related PNPLA7 is regulated by insulin and glucose. These seemingly disparate findings are not necessarily mutually exclusive, but we need to reconcile recent genetic findings with the historical body of toxicological data indicating that inhibition and aging of NTE are both necessary in order to produce neuropathy from exposure to certain OP compounds. Solving this mystery will be satisfying in itself, but it is also an enterprise likely to pay dividends by enhancing our understanding of the physiological and pathogenic roles of the PNPLA family of proteins in neurological health and disease, including a potential role for NTE in diabetic neuropathy.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23220002     DOI: 10.1016/j.cbi.2012.10.024

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  34 in total

1.  Novel mutations in the PNPLA6 gene in Boucher-Neuhäuser syndrome.

Authors:  Kishin Koh; Fumikazu Kobayashi; Michiaki Miwa; Kazumasa Shindo; Eiji Isozaki; Hiroyuki Ishiura; Shoji Tsuji; Yoshihisa Takiyama
Journal:  J Hum Genet       Date:  2015-01-29       Impact factor: 3.172

Review 2.  Organophosphate neurotoxicity to the voluntary motor system on the trail of environment-caused amyotrophic lateral sclerosis: the known, the misknown, and the unknown.

Authors:  Samantha J Merwin; Teresa Obis; Yanelli Nunez; Diane B Re
Journal:  Arch Toxicol       Date:  2017-01-09       Impact factor: 5.153

3.  Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474.

Authors:  Annelot C M van Esbroeck; Antonius P A Janssen; Armand B Cognetta; Daisuke Ogasawara; Guy Shpak; Mark van der Kroeg; Vasudev Kantae; Marc P Baggelaar; Femke M S de Vrij; Hui Deng; Marco Allarà; Filomena Fezza; Zhanmin Lin; Tom van der Wel; Marjolein Soethoudt; Elliot D Mock; Hans den Dulk; Ilse L Baak; Bogdan I Florea; Giel Hendriks; Luciano De Petrocellis; Herman S Overkleeft; Thomas Hankemeier; Chris I De Zeeuw; Vincenzo Di Marzo; Mauro Maccarrone; Benjamin F Cravatt; Steven A Kushner; Mario van der Stelt
Journal:  Science       Date:  2017-06-09       Impact factor: 47.728

Review 4.  Genetics of Amyotrophic Lateral Sclerosis.

Authors:  Mehdi Ghasemi; Robert H Brown
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

5.  PNPLA6 mutations cause Boucher-Neuhauser and Gordon Holmes syndromes as part of a broad neurodegenerative spectrum.

Authors:  Matthis Synofzik; Michael A Gonzalez; Charles Marques Lourenco; Marie Coutelier; Tobias B Haack; Adriana Rebelo; Didier Hannequin; Tim M Strom; Holger Prokisch; Christoph Kernstock; Alexandra Durr; Ludger Schöls; Marcos M Lima-Martínez; Amjad Farooq; Rebecca Schüle; Giovanni Stevanin; Wilson Marques; Stephan Züchner
Journal:  Brain       Date:  2013-12-19       Impact factor: 13.501

Review 6.  Positron emission tomography studies of organophosphate chemical threats and oxime countermeasures.

Authors:  Charles M Thompson; John M Gerdes; Henry F VanBrocklin
Journal:  Neurobiol Dis       Date:  2019-04-22       Impact factor: 5.996

Review 7.  Neurotoxicity of pesticides.

Authors:  Jason R Richardson; Vanessa Fitsanakis; Remco H S Westerink; Anumantha G Kanthasamy
Journal:  Acta Neuropathol       Date:  2019-06-13       Impact factor: 17.088

Review 8.  Organophosphorus Compounds at 80: Some Old and New Issues.

Authors:  Lucio G Costa
Journal:  Toxicol Sci       Date:  2018-03-01       Impact factor: 4.849

9.  Further studies toward a mouse model for biochemical assessment of neuropathic potential of organophosphorus compounds.

Authors:  Galina F Makhaeva; Elena V Rudakova; Nichole D Hein; Olga G Serebryakova; Nadezhda V Kovaleva; Natalia P Boltneva; John K Fink; Rudy J Richardson
Journal:  J Appl Toxicol       Date:  2014-01-07       Impact factor: 3.446

10.  Hypermethylation reduces the expression of PNPLA7 in hepatocellular carcinoma.

Authors:  Xiaojiao Zhang; Jun Zhang; Rui Wang; Shicheng Guo; Huilu Zhang; Yanyun Ma; Qingmei Liu; Haiyan Chu; Xianghong Xu; Yitong Zhang; Dongqin Yang; Jiucun Wang; Jie Liu
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.